A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD) [1]
The primary objective of this study is to evaluate the effectiveness and safety of RO7017773, a new medication, compared with placebo in the improvement of symptoms of ASD.
Study Length:
Approximately 5.5 months
Disorder/Condition:
Autism
Inclusion Criteria:
Males and Females, ages 15-45 with ASD
Study Title (brief):
A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD)
Study Description (brief):
The primary objective of this study is to evaluate the effectiveness and safety of RO7017773, a new medication, compared with placebo in the improvement of symptoms of ASD.
Study Contact:
Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org [2]
Study Location:
Nathan Kline Institute, Orangeburg, NY